Open Orphan Share Discussion Threads

[m5] 01/2/2021 11:15

I think some new to the share may not understand what CF means when he says "significant" We are in a situation now where can pick and choose the work we do. If it does not pay, and pay well, we can move on. DYOR.

[faz] 01/2/2021 10:19

12toes with respect what I see see under Advfn trades are not large sells. (25k, 21k and so on) There are many PIs here I would imagine that have shares well into the 100,000s. If you bought ORPH at 6p you could have 100k shares for £6k.

[m5] 01/2/2021 10:06

Ahhh OK, apologies if I have the wrong end of the stick.

[1gw] 01/2/2021 10:04

Article on SPACs may be of interest given their possible use by CF as an alternative (for ORPH's non-core assets) to a reverse into something like BiondVax. With this type of SPAC, the SPAC raises money through its own IPO and then acquires a target (ORPH's assets in this scenario).

The article suggests there are a lot of SPACs already out there with funds raised ready for the right acquisition.

"In today’s market, there’s [more than] 300 SPACs out there still looking for a deal.”

[troutisout] 01/2/2021 09:57

m5, I think he was talking about a separate RNS on current trading, not this contract specifically.

[12toes] 01/2/2021 09:32

The 2 drops24 -> 23.7523.75 -> 23.5 With blocks being dumped into any buys as usual

[m5] 01/2/2021 09:20

AdamB19781 Feb '21 - 09:07 - 11191 of 11191

Agreed, but for reasons discussed many times we don't get figures with these type of contracts.It's just the nature of the business. Unfortunately for potential new investors they don't mean a great deal, unless you are prepared to do some digging and then you realise these are substantial contracts with huge figures attached. As said above these contracts are very important, however these type of RNS's will not blow the doors off share price wise, as we are now well aware.

[adamb1978] 01/2/2021 09:07

Another nice announcement. Again though I think that it would be helpful to get some figures - for example, a post-period end trading update confirming that turnover was between x and y, and that profits were in-line with expectations.

[lako42] 01/2/2021 09:00

What price drop?

[gregb] 01/2/2021 09:00

One of us needs an appointment at Specsavers and it's not me!

[pierre oreilly] 01/2/2021 08:57

Doubt it, there's certainly no evidence of that, and the trades look like pis to me. Probably like you, sell and then say there are big sellers around. Probably hundreds of pis now sell on a 1p rise and then buy back when/if it drops back 0.5p. sounds a great way of making 50quid now and again. But when it just carries in rising and doesn't settle back, then all the 1p sellers lose out a lot.We'll see what insideish info we get from c at his next presentation, there'll be plenty of questions for him.

[12toes] 01/2/2021 08:49

I didn't see that price drop said no one ever.Big seller still dumping blocks into any rises

[inaminute] 01/2/2021 08:36

They underpin everything. Without them we would have the 'no profitability' brigade out in force. Strong management.

[lako42] 01/2/2021 08:23

Very important that these bread and butter contracts are still rolling in.

[lfdkmp] 01/2/2021 07:51

LOL

rivaldo seems we both have a thing about sticks

[lfdkmp] 01/2/2021 07:50

Don't think I've encountered a stunned silence to a positive RNS before.

Am I the only one who, with all the weekend comment about ORPH involvement in new COVID testing, was expecting a RNS with some breakthrough news?

The RNS we got was more of the "business as usual" variety.

Wondering if I (suspect among many others) had not only got the wrong end of the stick over the weekend, I'd even got the wrong stick.

[rivaldo] 01/2/2021 07:49

Excellent news this morning - and more news flow than you can shake a stick at is likely to flow over the coming weeks and months.

[garth] 01/2/2021 07:15

Masaaki Sawa, Ph.D., Chief Scientific Officer and Head of Research and Development at Carna Biosciences, said: "The partnership with Venn Life Sciences complements our clinical development team and underlines our commitment to become a clinical stage company. By continuing the collaboration with the Venn team, we will accelerate our drug development"


About Open Orphan plc ( www.openorphan.com )

The Company has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. As announced in early March, Open Orphan is rapidly advancing a number of Coronavirus challenge study models and expects to be helping many COVID-19 vaccine development companies to test their vaccines. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each hVIVO also works with companies in the UK and Ireland to provide COVID-19 testing to staff to protect staff and customers from a workplace COVID-19 outbreak through its COVID Clear offering.

[marvelman] 01/2/2021 07:13

Well he promised a new contract every month and that is what he his giving us

[orphan1] 31/1/2021 22:31

Beep BeepThat's the sound of my alarm in the morningLooking forward to 7am

[discojames] 31/1/2021 20:31

Yes that was acacia, he never said anything about offloading for Invesco as he hasn't even done am interview since their holding notification

[klosters65] 31/1/2021 20:26

Or was that another institution purported to be offloading prior to Invesco?